FindTrial
Sign In

CBP-201

DRUG6 trials

Sponsors

Connect Biopharm LLC

Conditions

Atopic DermatitisChronic Rhinosinusitis With Nasal PolypsModerate to Severe Persistent AsthmaModerate-to-severe Atopic Dermatitis

Phase 2

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
CompletedNCT04444752
Connect Biopharm LLCModerate-to-severe Atopic Dermatitis
Start: 2020-07-17End: 2021-09-22Updated: 2023-08-01
Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
CompletedNCT04773678
Connect Biopharm LLCModerate to Severe Persistent Asthma
Start: 2021-05-11End: 2023-09-28Updated: 2024-03-29
A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
TerminatedNCT04783389
Connect Biopharm LLCChronic Rhinosinusitis With Nasal Polyps
Start: 2021-06-16End: 2022-06-10Updated: 2023-10-17
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
CompletedNCT05017480
Connect Biopharm LLCModerate-to-severe Atopic Dermatitis
Start: 2021-08-31End: 2023-09-28Updated: 2024-05-01
A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD
NCT05905133
Connect Biopharm LLCAtopic Dermatitis
Start: 2023-07-15End: 2024-06-30Updated: 2023-12-11

Phase 3

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis
WithdrawnNCT05614817
Connect Biopharm LLCAtopic Dermatitis
Start: 2022-12-31End: 2025-07-31Updated: 2023-03-21

Related Papers

Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase 2b Randomized Clinical Trial.
2026-09-09
Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (SEASIDE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing.
2026-01-01
Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis
JEADV Clinical Practice2025-11-05
Effect of Rademikibart on Blood Eosinophil Counts in Patients With Asthma: Is There an IL-4Rα Class Effect?
American Journal of Respiratory and Critical Care Medicine2025-05-01
Efficacy of Rademikibart in COPD-like Patients: Sub-analyses from the Phase 2b Trial in Patients With Moderate-to-Severe Asthma
American Journal of Respiratory and Critical Care Medicine2025-05-01
Rademikibart Treatment for Moderate-to-Severe Uncontrolled Asthma: A Phase 2B Randomized Clinical Trial
American Journal of Respiratory and Critical Care Medicine2025-02-254 citations
712 - Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (S<u>EASI</u>DE CHINA)
British Journal of Dermatology2024-08-011 citations
438 Potentially greater efficacy with CBP-201 for adults with severe vs. moderate atopic dermatitis at baseline: subgroup analyses from the WW001 phase 2 randomized trial
British Journal of Dermatology2023-06-011 citations